Published in J Clin Microbiol on April 04, 2007
Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol (2012) 2.82
Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J Clin Microbiol (2009) 1.99
Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. J Clin Microbiol (2009) 1.22
Validation of 24-hour fluconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: results from a global Candida antifungal surveillance program. J Clin Microbiol (2008) 1.05
Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program. J Clin Microbiol (2011) 1.00
Agar disk diffusion and automated microbroth dilution produce similar antimicrobial susceptibility testing results for Salmonella serotypes Newport, Typhimurium, and 4,5,12:i-, but differ in economic cost. Foodborne Pathog Dis (2011) 0.85
Rapid identification of bacteria and Candida using PNA-FISH from blood and peritoneal fluid cultures: a retrospective clinical study. Ann Clin Microbiol Antimicrob (2013) 0.84
Validation of 24-hour flucytosine MIC determination by comparison with 48-hour determination by the Clinical and Laboratory Standards Institute M27-A3 broth microdilution reference method. J Clin Microbiol (2011) 0.82
Antifungal susceptibility testing: current role from the clinical laboratory perspective. Mediterr J Hematol Infect Dis (2014) 0.77
Guidelines for treatment of candidiasis. Clin Infect Dis (2003) 5.55
Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother (2005) 5.35
Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis (2006) 5.27
Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev (2006) 2.39
Peptide nucleic acid fluorescence in situ hybridization-based identification of Candida albicans and its impact on mortality and antifungal therapy costs. J Clin Microbiol (2006) 2.15
Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Chemother (2005) 2.08
Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol (2004) 2.06
Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol (2006) 1.78
Cost savings with implementation of PNA FISH testing for identification of Candida albicans in blood cultures. Diagn Microbiol Infect Dis (2006) 1.72
Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis (2005) 1.68
Newer systemic antifungal agents : pharmacokinetics, safety and efficacy. Drugs (2004) 1.67
Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother (2006) 1.62
The role of antifungal susceptibility testing in the therapy of candidiasis. Diagn Microbiol Infect Dis (2004) 1.58
Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore) (2003) 1.51
Real-time antifungal susceptibility screening aids management of invasive yeast infections in immunocompromised patients. J Antimicrob Chemother (2002) 1.17
Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemia. Diagn Microbiol Infect Dis (2004) 1.08
Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med (2006) 4.50
Clostridium difficile ribotype does not predict severe infection. Clin Infect Dis (2012) 4.34
Detection of the Klebsiella pneumoniae carbapenemase type 2 Carbapenem-hydrolyzing enzyme in clinical isolates of Citrobacter freundii and K. oxytoca carrying a common plasmid. J Clin Microbiol (2008) 2.13
Blood culture contamination: a randomized trial evaluating the comparative effectiveness of 3 skin antiseptic interventions. Infect Control Hosp Epidemiol (2012) 1.61
Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. J Infect Dis (2008) 1.58
Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS One (2012) 1.40
Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. Diagn Microbiol Infect Dis (2010) 1.39
Impact of mecA gene testing and intervention by infectious disease clinical pharmacists on time to optimal antimicrobial therapy for Staphylococcus aureus bacteremia at a University Hospital. J Clin Microbiol (2008) 1.26
Autopsy findings in eight patients with fatal H1N1 influenza. Am J Clin Pathol (2010) 1.25
Multicenter evaluation of the BD Max GBS assay for detection of group B streptococci in prenatal vaginal and rectal screening swab specimens from pregnant women. J Clin Microbiol (2010) 1.16
Asynchronous magnetic bead rotation (AMBR) biosensor in microfluidic droplets for rapid bacterial growth and susceptibility measurements. Lab Chip (2011) 1.12
Comparison of chromogenic media to BD GeneOhm methicillin-resistant Staphylococcus aureus (MRSA) PCR for detection of MRSA in nasal swabs. J Clin Microbiol (2009) 1.10
Clostridium difficile ribotype diversity at six health care institutions in the United States. J Clin Microbiol (2013) 1.04
Monitoring the growth and drug susceptibility of individual bacteria using asynchronous magnetic bead rotation sensors. Biosens Bioelectron (2010) 1.03
A simplified sequence-based identification scheme for Bordetella reveals several putative novel species. J Clin Microbiol (2013) 1.00
Culture-based method with performance comparable to that of PCR-based methods for detection of group B Streptococcus in screening samples from pregnant women. J Clin Microbiol (2013) 0.97
Impact of hourly emergency department patient volume on blood culture contamination and diagnostic yield. J Clin Microbiol (2013) 0.96
Non-toxigenic Clostridium sordellii: clinical and microbiological features of a case of cholangitis-associated bacteremia. Anaerobe (2011) 0.93
Multicenter clinical evaluation of VRESelect agar for identification of vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. J Clin Microbiol (2013) 0.91
The impact of delaying the initiation of appropriate antifungal treatment for Candida bloodstream infection. Med Mycol (2010) 0.90
Development and evaluation of a PCR and mass spectroscopy (PCR-MS)-based method for quantitative, type-specific detection of human papillomavirus. J Virol Methods (2009) 0.90
Emergence of a novel extended-spectrum-β-lactamase (ESBL)-producing, fluoroquinolone-resistant clone of extraintestinal pathogenic Escherichia coli in Kumasi, Ghana. J Clin Microbiol (2012) 0.89
Pseudo-outbreak of Clostridium sordellii infection following probable cross-contamination in a hospital clinical microbiology laboratory. Infect Control Hosp Epidemiol (2010) 0.89
Self-assembled magnetic bead biosensor for measuring bacterial growth and antimicrobial susceptibility testing. Small (2012) 0.88
Evolving role of early antifungals in the adult intensive care unit. Crit Care Med (2009) 0.86
Mandibular Actinomyces osteomyelitis complicating florid cemento-osseous dysplasia: case report. BMC Oral Health (2011) 0.83
Major variation in MICs of tigecycline in Gram-negative bacilli as a function of testing method. J Clin Microbiol (2014) 0.83
Complement c5a generation by staphylococcal biofilms. Shock (2013) 0.82
Actinomyces infectious crystalline keratopathy. Arch Ophthalmol (2011) 0.78
The nose knows not: poor predictive value of stool sample odor for detection of Clostridium difficile. Clin Infect Dis (2012) 0.76
Reply to McDonald. Clin Infect Dis (2012) 0.75
Reply to Walker et al. Clin Infect Dis (2013) 0.75
Supratherapeutic oseltamivir levels during continuous dialysis: an expected risk. Intensive Care Med (2010) 0.75
Antibiotic allergy. N Engl J Med (2006) 0.75
Identifying patients at risk of chronic kidney disease. Am Fam Physician (2007) 0.75
Antifungal Prophylaxis in Lung Transplant Recipients. Transplantation (2016) 0.75